Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $58.68 USD
Change Today -6.38 / -9.81%
Volume 2.2M
KITE On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Open
$66.09
Previous Close
$65.06
Day High
$66.40
Day Low
$57.84
52 Week High
01/15/15 - $89.21
52 Week Low
07/16/14 - $21.00
Market Cap
2.5B
Average Volume 10 Days
1.2M
EPS TTM
$-3.50
Shares Outstanding
42.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KITE PHARMA INC (KITE)

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. It has research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; and collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

72 Employees
Last Reported Date: 03/26/15
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $16.7K
Vice President of Translation Medicine
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2013.

kite pharma inc (KITE) Key Developments

Kite Pharma, Inc. Presents at 2015 Jefferies Immuno-Oncology Summit, Apr-15-2015 08:10 AM

Kite Pharma, Inc. Presents at 2015 Jefferies Immuno-Oncology Summit, Apr-15-2015 08:10 AM. Venue: Boston, Massachusetts, United States. Speakers: Arie S. Belldegrun, Founder, Executive Chairman, Chief Executive Officer and President.

Kite Pharma, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Kite Pharma, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $13,255,000 against $2,399,000 a year ago. Net loss was $13,019,000 against $2,378, 000 a year ago. Net loss attributable to common stockholders was $13,019,000 against $2,954,000 a year ago. Basic and diluted net loss per share was $0.33 against $0.54 a year ago. Net loss attributable to common stockholders - Non-GAAP was $7,509,000. Net loss attributable to common stockholders, basic and diluted - Non-GAAP was $0.19. For the year, the company reported loss from operations of $36,658,000 against $6,427,000 a year ago. Net loss was $42,569,000 against $6,366, 000 a year ago. Net loss attributable to common stockholders was $43,658,000 against $7,801,000 a year ago. Basic and diluted net loss per share was $1.91 against $1.43 a year ago. Net loss attributable to common stockholders - Non-GAAP was $21,399,000. Net loss attributable to common stockholders, basic and diluted - Non-GAAP was $0.94.

Kite Pharma, Inc. Amends Cooperative Research and Development Agreement with National Cancer Institute

Kite Pharma, Inc. announced that the company has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The amendment will encompass emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. In addition, new T cell receptor (TCR) and new chimeric antigen receptor (CAR) product candidates targeting solid tumors have been added to the collaboration. The amendment broadens Kite's ongoing research collaboration with the Surgery Branch at the NCI, led by Steven A. Rosenberg, M.D., Ph.D. and provides additional product candidates for Kite's growing pipeline. Under Kite's amended agreement with the NCI, the additional programs will encompass: Methods of rapidly identifying and developing TCR product candidates targeted against neo-antigens; Optimizing new methods to manufacture this new class of individualized therapies; Developing additional TCR product candidates retrovirally engineered to target tumor antigens, including for the treatment of colorectal and lung cancers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $58.68 USD -6.38

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies
 

Industry Analysis

KITE

Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit www.kitepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.